Published in FDA Law Weekly, December 16th, 2004
In clinical studies, Vesicare 5 mg and 10 mg (Yamanouchi Pharmaceutical Co., Ltd.) showed clinical and statistical improvements in all symptoms of OAB. Specifically, once-daily Vesicare was found to significantly reduce the number of incontinence episodes for patients during a 12-week study period.
OAB is a medical condition that causes the bladder muscle (known as the detrusor muscle) to contract while the bladder is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.